Form 8-K · Current Report · Filed 2025-07-28
Revvity Reports Second Quarter 2025 Financial Results
Revvity, Inc. reported its financial results for the second quarter of 2025 on July 28, 2025. The company announced revenue of $720 million, reflecting a 4% reported growth and 3% organic growth. GAAP EPS was $0.46, and adjusted EPS from continuing operations was $1.18. Revvity also updated its full-year 2025 guidance, raising its revenue guidance to $2.84-$2.88 billion and adjusting its adjusted EPS guidance to a range of $4.85 to $4.95. Both Life Sciences and Diagnostics segments showed growth, with Life Sciences achieving a 5% revenue increase and Diagnostics at 3%. The company's cash position stood at $992.99 million at the end of Q2 2025.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-25-000022
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$103.67
Next session
-8.9%
Since filing
+41.5%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a prominent company in the healthcare and biological sciences field, offering a comprehensive suite of solutions aimed at improving global health outcomes. The company's core focus lies in delivering innovative products and services that range from diagnostic tools to advanced analytical capabilities for life sciences research. Revvity serves a wide array of sectors including biotechnology, pharmaceuticals, and clinical diagnostics, providing essential tools and data analytics that aid in disease discovery, drug development, and health monitoring. The company's expertise in deploying cutting-edge technologies further reinforces its position as a critical enabler of scientific research and innovation. With its global reach and commitment to enhancing healthcare delivery, Revvity Inc. plays a pivotal role in advancing the capabilities of medical and scientific communities worldwide, driving progress in critical areas such as personalized medicine and preventive healthcare.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.